In June 2021, Biogen / Eisai’s anti-Aβ MAb Aduhelm received accelerated approval from the FDA for the treatment of Alzheimer’s disease (AD), making it the first potential DMT approved for this disease—an event marked by considerable controversy. Other DMTs may soon follow in the United States and potentially other markets (Eisai / Biogen’s lecanemab, Eli Lilly’s donanemab, and Novo Nordisk’s semaglutide). Meanwhile, hope remains for therapies from Lundbeck, Otsuka, Avanir, BioXcel, and Axsome that are in late-phase development to treat key neuropsychiatric symptoms associated with AD. The launch of these potential blockbusters could meaningfully alter the dynamics of this market, driven by clear need, strong market demand, and premium pricing.
QUESTIONS ANSWERED
How large is the treatable AD population? What will be the impact of future anti-Aβ MAbs on diagnosis / drug treatment rates if these agents become available and accessible for the treatment of early AD?
What are KOLs’ opinions of recently launched therapies (e.g., Corium’s Adlarity) and other key symptomatic and disease-modifying therapies in development for AD?
What commercial uptake can Rexulti, AVP -786, Auvelity (AXS-05) expect if they launch for AD agitation?
What are the drivers and constrainers of the AD market, and how might they change over the forecast period as premium-priced agents enter the market?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.